Capital Advisors Inc. OK lowered its stake in shares of Allergan PLC. (NYSE:AGN) by 2.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,776 shares of the company’s stock after selling 1,416 shares during the quarter. Allergan PLC. comprises about 0.9% of Capital Advisors Inc. OK’s holdings, making the stock its 26th largest position. Capital Advisors Inc. OK’s holdings in Allergan PLC. were worth $14,774,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Jacobi Capital Management LLC increased its stake in shares of Allergan PLC. by 4.9% during the 1st quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after acquiring an additional 22 shares during the last quarter. JNBA Financial Advisors increased its stake in shares of Allergan PLC. by 2.5% during the 1st quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after acquiring an additional 12 shares during the last quarter. Pacific Center for Financial Services increased its stake in shares of Allergan PLC. by 805.1% during the 1st quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock valued at $128,000 after acquiring an additional 475 shares during the last quarter. Hudock Capital Group LLC increased its stake in shares of Allergan PLC. by 0.4% during the 2nd quarter. Hudock Capital Group LLC now owns 571 shares of the company’s stock valued at $138,000 after acquiring an additional 2 shares during the last quarter. Finally, Ropes Wealth Advisors LLC increased its stake in shares of Allergan PLC. by 31.0% during the 1st quarter. Ropes Wealth Advisors LLC now owns 575 shares of the company’s stock valued at $137,000 after acquiring an additional 136 shares during the last quarter. 82.02% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/22/allergan-plc-agn-shares-sold-by-capital-advisors-inc-ok.html.

Allergan PLC. (NYSE:AGN) opened at 202.66 on Friday. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The stock has a market capitalization of $67.75 billion, a PE ratio of 6.17 and a beta of 1.18. The stock’s 50 day moving average price is $229.79 and its 200 day moving average price is $236.07.

Allergan PLC. (NYSE:AGN) last released its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company’s revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the firm posted $3.35 EPS. Equities research analysts forecast that Allergan PLC. will post $16.26 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 15th. Shareholders of record on Friday, August 18th were issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a yield of 1.33%. The ex-dividend date of this dividend was Wednesday, August 16th. Allergan PLC.’s dividend payout ratio (DPR) is currently 9.95%.

AGN has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price objective for the company in a research note on Tuesday, July 11th. Cowen and Company reiterated an “outperform” rating and set a $400.00 target price on shares of Allergan PLC. in a report on Tuesday, August 29th. Morgan Stanley cut Allergan PLC. from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $284.00 to $228.00 in a report on Wednesday. Wells Fargo & Company reiterated an “outperform” rating on shares of Allergan PLC. in a report on Monday, September 11th. Finally, Sanford C. Bernstein reiterated an “outperform” rating on shares of Allergan PLC. in a report on Thursday, May 25th. One analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company’s stock. Allergan PLC. presently has an average rating of “Buy” and an average price target of $273.34.

About Allergan PLC.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.